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Poster Session-I 77Conclusion: Dose targeting of busulfan to an AUC above 74
mg*h/L prevents graft failures in patients with non-malignant dis-
eases and is not associated with higher toxicity. Outcomes might
be optimized further by targeting a narrower AUC window: a mini-
mum AUC to ensure engraftment, and a maximum to minimize the
busulfan-associated toxicity.208
GROWTH AND CGVHD IN PEDIATRIC PATIENTS UNDERGOING REDUCED
INTENSITY CONDITIONING FOR HEMATOPOIETIC STEM CELL TRANS-
PLANT AS COMPARED TO TRADITIONAL MYELOABLATIVE CONDITION-
ING
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Dilley, K.J.1,3 1Children’s Memorial Hospital, Chicago, IL; 2Harvard
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Background: Reduced intensity conditioning (RI) regimens are
used as an alternative to traditional myeloablative conditioning
(MA) for allogeneic hematopoietic stem cell transplant (HSCT) in
children. The main rationale is to allow tumor kill while decreasing
the degree of acute toxicity due to conditioning regimen, which
could potentially also decrease the occurrence of late effects.
Objective: To examine growth parameters and prevalence of
chronic graft versus host disease (CGvHD) at specific timepoints
in pediatric survivors of RI HSCT as compared to matched controls
who received MA.
Design/Methods: Medical record review of all patients who re-
ceived a RI HSCT from 2000 to 5/2007 at a single institution, ex-
cluding patients who ever received .1 HSCT, survived\100 days
post RI HSCT or had a primary diagnosis that would affect growth
directly. Remaining patients were matched to MA recipients by age
at HSCT andmalignancy yes/no. It was not always possible tomatch
for HSC source. Any occurence of CGvHD (McNemar test) and
growth data (paired T-test) were analyzed at 1y and latest follow-
up available.
Results:MAmatches were found for 34/44 patients who received
a single RI HSCT. Mean age at first transplant was 9.45y for RI and
9.84y forMA (p5 0.15). 20/34 pairs (59%) were same gender. 24/34
pairs (71%) were matched for related/unrelated, and 17/34 pairs
(50%) agreed for both matched/unmatched and related/unrelated.
21/34 (62%) were matched for HSC source, all mismatches were
RI peripheral blood HSCs with MA bone marrow (n 5 12) or
cord blood (n 5 1). The length of follow-up to latest visit differed
between RI patients at mean 966 (range 462–2512) days and MA at
2025 (range 525–4538) days (p5 0.006). No differences seen in Ta-
ble 1 were significant, although 1 year height Z scores approached
significance with p 5 0.051.
Growth parameters and prevalence of CGvHD at specific
timepoints
RI MA RI MA1 year (n531) Latest F/U (n531)Extensive CGvHD 3/31 (10%) 6/31 (19%) 2/31 (6%) 1/31 (3%)
1 year (n515)1 Latest F/U (n510)1Height Z score –0.78 –0.14 –0.86 –0.47
BMI Z score 0.13 0.98 1.01 1.311Full growth parameters, especially height, were not available at all visits.
Conclusions: At specific follow-up timepoints, there was no dif-
ference in CGvHD prevalence or in growth parameters between
age- and diagnosis-matched RI and MA HSCT recipients. This
study did not allow survival curve analysis of CGvHD, as occurrence
was only assessed at specific timepoints. Height Z scores were less
than zero at all timepoints, indicating that growth is affected both
by RI andMA regimens. Longer follow-upwill be necessary to ascer-
tain if growth effects are different over time between RI and MA re-
cipients, and this study by design will also assess differences in late
effects such as endocrine or other organ system dysfunction.209
REDUCED INTENSITY CONDITIONING (RIC) IS ASSOCIATED WITH A SIG-
NIFICANT DECREASE IN DAY 1100 NON-RELAPSE MORTALITY (NRM),
GRADE II-IV AGVHD AND OVERALL SURVIVAL (OS) IN PEDIATRIC RECIP-
IENTS FOLLOWING CORD BLOOD TRANSPLANTATION (CBT)
Cairo, M.S.1,2,3, Jin, Z.4, van de Ven, C.1, Tallamy, B.1, Schonfeld, T.1,
Moore, V.1, Harrison, L.1, Morris, E.1, Bhatia, M.1, George, D.1,
Garvin, J.H.1, Bradley, M.B.1, Schwartz, J.3, Baxter-Lowe, L.A.5,
Satwani, P.1 1Morgan Stanley Children’s Hospital New York Presbyte-
rian, Columbia University, New York, NY; 2Columbia University, New
York, NY; 3Columbia University, New York, NY; 4Columbia University,
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We and others have demonstrated that myeloablative condition-
ing (MAC) and CBT results in a high engraftment rate and lower
severe AGVHD rate but a 20–40% incidence of Day 1100 NRM
(Cairo et al BBMT, 2008). RIC and AlloSCT in adults have been
associated with a decrease in acute toxicity and NRM (Satwani/
Cairo et al BBMT, 2005). Our group recently demonstrated the
safety and sustained high donor chimerism following RIC and
UCBT in pediatric recipients (Bradley/Cairo et al BMT, 2007).
In this study we investigated the risk factors associated with Day
1100 NRM, Grade II-IV AGVHD and OS in 101 consecutive
CBT pediatric recipients. Probability of Day 1100 NRM and OS
were calculated by Kaplan Meier estimates. Continuous variables
are summarized as mean 6 SD and categorical variables as %.
Risk factors for Grade II-IV AGVHD and Day1100 NRMwas as-
sessed by logistic regression and and OS was assessed by Cox pro-
portional hazards; variables \0.2 in univariate were included in
multivariate analyses. Risk factors: RIC vs MAC, average vs poor
risk, malignant/non, HLA 4/6 vs $4/6, CMV donor/recipient,
CD34\2.3 vs $2.3  105 CD34/kg, TNC 3, $3\5, $5  107
TNC/kg, Grade II-IV AGVHD, chronic GVHD. 101 pts, age
7.6 6 6.5 yrs; M/F 60/40%; MAC/RIC 55/45%; average/poor
risk 74/26%; CMV -/- 26%; HLA 4/6 52%; malignant/non 66/
34%. Median time to ANC and platelet recovery was similar be-
tween RIC and MAC CBT (24 vs 24) and (59 vs 64) d, respectively.
Day 180 and 365 chimerism was also similar (84 vs 89%) and (89 vs
92%), respectively. However, the probability of Grade II-IV
AGVHD was significantly less following RIC 20% (CI95 8.3%–
31.7%) vs 42.9% (CI95 29.9%–55.8%%) (p\ 0.015). Multivariate
analysis demonstrated the following independent risk factors in
Grade II-IV AGVHD: High CD34 hazard ratio (HR): 3.1,
p\0.02; HLA 4/6 HR: 4.2, p\0.007 and MAC HR: 4.1,
p\0.005. Day 1100 NRM was significantly less following RIC
2.3% (CI95 0–6.7%) vs. 26.1% (CI95 14.3%–37.8%), p\0.002.
The only significant factor in Day 1100 NRM was MAC HR:
27.2, p\0.005. Lastly, 3yr OS was significantly improved following
RIC 56% (CI95 37–70) vs MAC 28% (CI95 16–40) and the follow-
ing risk factors: Low vs High CD34 HR: 1.0 vs 0.38, p\0.004;
and MAC HR: 2.9, p\0.001 were associated with a significant
improvement in OS. In summary, RIC was the single most impor-
tant risk factor associated with a significant reduction in Grade II-
IV AGVHD, Day 100 NRM and OS in pediatric recipients
following CBT.210
DIFFERENCES IN MONITORING AND TREATMENT OF CRITICALLY ILL
CHILDREN DURING OR AFTER HEMATOPOETIC STEM CELL TRANSPLANT
McArthur, J.A.1, Christensen, M.A.1, Tamburro, R.F.2, Jouvet, P.3,
Pettersen, G.3 1Medical College of Wisconsin, Milwaukee, WI; 2Pennsyl-
vania State University, Hershey, PA; 3St. Justine Hospital, Montreal,
QC, Canada
Background: Pediatric hematopoetic stem cell transplant
(HSCT) recipients requiring critical care services historically have
poor outcomes. There appears to be a wide range of clinical ap-
proaches to this patient population. Clinical trials utilizing evi-
denced-based protocols are needed to improve outcomes. A better
understanding of the variations in care of these patients is needed
to design future trials. The Pediatric Acute Lung Injury and Sepsis
Investigators (PALISI) Network surveyed the most active United
States pediatricHSCTprograms regarding the care provided to crit-
ically ill patients.
78 Poster Session-IMethods: The surveyed centers accounted for 75% of all pediat-
ric HSCT and were identified by querying the CIBMTR. Two indi-
viduals from each of these institutions were survey recipients; one
from the Division of Pediatric Critical Care Medicine (PCCM)
and the other from the Division of HSCT. The survey was con-
ducted electronically using SurveyMonkey allowing data to remain
anonymous. A four-choice Lickert scale was used for clinical ques-
tions.
Results: Completed surveys were returned from both the HSCT
and PCCM physicians in 22 programs. The percentage of programs
that always or commonly perform the following interventions on the
HSCT unit are as follows: central venous pressure monitoring
(18%), 100% non-rebreather mask (50%), non-invasive ventila-
tion(18%), intermittent hemodialysis (41%), continuous veno-
venous hemofiltration (0%), dopamine (36%) with the maximal
dose varying by center. In terms of care by PCCM physicians,
most all programs use 100% oxygen, non-invasive ventilation and
aggressive diuresis prior to intubation; 2/3 of programs attempt renal
replacement therapy (RRT). 59% of PCCM physicians always or
commonly offer intubation as a time limited trial to HSCT patients;
18% never offer this option. Non-conventional respiratory therapies
commonly offered to HSCT patients include high frequency oscilla-
tory ventilation, nitric oxide and RRT. Surfactant use is less common
and ECMO use is rare.
Conclusion: There is a notable variation in the level of monitor-
ing and support offered on pediatric HSCT units as well as therapies
provided by PCCM physicians to HSCT patients. Not only is this
data is important for the design of clinical trials, but studies should
be done to determine if these practice variations impact patient out-
comes.211
SURVIVAL FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION
FOR CONGENITAL IMMUNODEFICIENCY AND METABOLIC DISORDERS
Horwitz,M.E.1, Tunes da Silva, G.2, Eapen,M.2, Horwitz, E.M.3 1Duke
University Medical Center, Durham, NC; 2Medical College of Wisconsin,
Milwaukee, WI; 3The Children’s Hospital of Philadelphia and University
of Pennsylvania School of Medicine, Philadelphia, PA
We compared outcomes of allogeneic stem cell transplantation
(SCT) for congenital immunodeficiency and metabolic disorders
to children of a similar age who received SCT for acute leukemia
in first or second complete remission. This analysis was undertaken
to address a reluctance among many physicians to refer children
with certain congenital immunodeficiency or metabolic disorders
for early SCT. The study population includes 343 children (#5
years) with congenital immunodeficiency (129 with severe com-
bined immunodeficiency [SCID]; 214 with non-SCID) and 354
children with metabolic disorders. This population was compared
to 622 age-matched children with acute leukemia (the control pop-
ulation). All transplantations occurred between 1995 and 2005 and
the transplant conditioning regimen was myeloablative. In univari-
ate analysis, 5-year overall survival was higher after HLA-matched
sibling donor transplants for SCID (80%), non-SCID (84%) and
metabolic disorders (78%) compared to the control group (51%,
p\0.001). Amongst recipients of unrelated donor SCT, 5-year
overall survival was higher for non-SCID patients compared to con-
trols (66% vs 50%, p5 0.05). The 5-year survival rates were similar
after unrelated donor SCT for SCID (41%), metabolic (51%) and
good risk acute leukemia, the control group (50%). In multivariate
analysis, donor type was the only factor associated with survival;
mortality rates were higher after unrelated donor SCT (odds ratio
1.49, 95% CI 1.02–2.16, p 5 0.04). Further, we observed no differ-
ences in survival after unrelated donor bone marrow and cord blood
SCT. The data suggest children with congenital immunodeficiency
and metabolic disorders who receive an unrelated donor SCT have
similar survival rates as children with good risk acute leukemia. The
sub-group of children with non-SCID diseases fare the best, with
a 5-year overall survival that exceeds that of age-matched patients
with acute leukemia. Therefore prompt referral for SCT for these
children, before mounting comorbidities render them ineligible,
should be encouraged even in the absence of an HLA-matched sib-
ling donor.212
REDUCED TOXICITY MYELOABLATIVE CONDITIONING REGIMEN WITH
BUSULFAN, FLUDARABINE AND ALEMTUZUMAB FOR CHILDREN
WITH NON-MALIGNANT DISORDERS, MYELODYSPLASTIC SYNDROME
(MDS) AND MYELOID MALIGNANCIES
Horn, B.N., Dvorak, C.C., Huang, J., Englert, L., Kavanau, K.,
Cowan, M.J. University of California San Francisco, San Francisco, CA
Major problems with Busulfan/Cyclophosphamide (Bu/Cy) con-
ditioning are acute toxicities and graft failure. In 2000, we replaced
Bu/Cy conditioning with targeted i.v. Busulfan/Fludarabine/rabbit
ATG (Bu/Flu/rATG) which effectively reduced acute toxicities;
however, graft failure rate remained high (21%). In 2004, we intro-
duced targeted i.v. Busulfan/Fludarabine and Alemtuzumab (Bu/
Flu/Campath) to reduce graft failure rate. We describe and compare
the outcomes of the first 21 Bu/Flu/Campath study patients (median
age 8, range 1–16 years) with those of previously published 19 By/
Flu/rATG study patients. Diagnoses included MDS or myeloid ma-
lignancy (N 5 5), hemoglobinopathy (N 5 3), non-SCID primary
immunodeficiency (N 5 6), aplastic anemia (N 5 2), autoimmune
disorders (N 5 2), and metabolic disorders (N 5 3). The donors
included$8/8 HLA-matched (N 5 6) and one antigen mismatched
(N 5 4) unrelated volunteers, and fully matched related donors
(N 5 11). Stem cell sources were peripheral blood (N 5 9), bone
marrow (N 5 10) or combined sources (N 5 2). 19/20 evaluable
patients engrafted. One patient withHurler’s disease developed graft
rejection 40 days post transplant but was rescued with a 2nd trans-
plant. The median follow-up of living patients is 21 months (range
4.3–51 months). Estimated 2-year post-transplant overall and
event-free survival rates were 83 6 9% and 71 6 11%, respectively,
which is similar to survival in the Bu/Flu/rATG study (896 7% and
74 6 10%). Three patients died (at 1, 5, and 12 months post trans-
plant) due to intracranial hemorrhage in 1 patient with Evans
syndrome, Aspergillus infection and GVHD in 1 patient with adre-
nal leukodystrophy (ALD), and disease progression and GVHD in 1
patient with ALD. One patient with MDS relapsed 1 year following
the transplant, but is alive following the 2nd successful transplant.
CMV reactivated in 47% (7/15) patients who were at risk for reacti-
vation and was successfully treated in all. Only 1 patient developed
mild VOD (maximum total bilirubin 3.4 mg/dl). The incidence of
acute and chronic GVHDwas 15% each, respectively. At last follow
up 85% of patients remain mixed chimeras. Bu/Flu/Campath condi-
tioning was well tolerated and resulted in durable mixed chimerism
in the majority of patients. Compared with Bu/Flu/rATG, Bu/Flu/
Campath conditioning resulted in significantly reduced graft rejec-
tion rate (2-tailed Fisher’s exact p 5 0.03) in mismatched MUD
transplants, but it did not improve overall survival or event free-
survival.213
SECOND ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) IN PEDIAT-
RIC PATIENTS
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Graft rejection and/or disease relapse after allogeneic SCT are
ominous events that are often associated with dismal outcome; sec-
ond SCTmay be considered as a salvage alternative in these patients
(pts) but is generally regarded as a procedure that is associated with
high morbidity and mortality. In the pediatric population, the data
on the outcome of second SCT are sketchy and scarce. We present
here our experience in 51 pediatric pts who underwent a second
SCT at our institution (KFSHRC).
Patients and methods: From May 1996 until May 2008, 51 pts
with graft failure or disease relapse after SCT (24 females and 27
males) underwent second SCT at KFSHRC; 17 pts had leukemia,
16 pts had non-malignant hematological disorders (NMHD), 16
pts had immune deficiency disorders (IMD), and 2 pts had meta-
bolic disorders. 35 pts were reconditioned with myeloablative reg-
imens (including 19 pts with TBI-regimens), 7 pts with
